oxidopamine has been researched along with Anxiety in 30 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
Excerpt | Relevance | Reference |
---|---|---|
"Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 7.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
"Hesperidin treatment was also capable to increase striatal levels of dopamine and its metabolite 3,4-dihydroxyphenylacetic acid and protects against the impairment of dopaminergic neurons in the substantia nigra pars compacta (SNpc) (p < 0." | 5.56 | Hesperidin Ameliorates Anxiety-Depressive-Like Behavior in 6-OHDA Model of Parkinson's Disease by Regulating Striatal Cytokine and Neurotrophic Factors Levels and Dopaminergic Innervation Loss in the Striatum of Mice. ( Antunes, MS; Araújo, SM; Boeira, SP; Bortolotto, VC; Cattelan Souza, L; Ladd, AABL; Ladd, FVL; Moreira, AL; Nogueira, CW; Prigol, M; Silva, MRP, 2020) |
"Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 3.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
"Hesperidin treatment was also capable to increase striatal levels of dopamine and its metabolite 3,4-dihydroxyphenylacetic acid and protects against the impairment of dopaminergic neurons in the substantia nigra pars compacta (SNpc) (p < 0." | 1.56 | Hesperidin Ameliorates Anxiety-Depressive-Like Behavior in 6-OHDA Model of Parkinson's Disease by Regulating Striatal Cytokine and Neurotrophic Factors Levels and Dopaminergic Innervation Loss in the Striatum of Mice. ( Antunes, MS; Araújo, SM; Boeira, SP; Bortolotto, VC; Cattelan Souza, L; Ladd, AABL; Ladd, FVL; Moreira, AL; Nogueira, CW; Prigol, M; Silva, MRP, 2020) |
"Anxiety in Parkinson's disease may represent a physiological reaction to the development of other symptoms during disease progression." | 1.51 | Anxiety-like behavior induced by 6-OHDA animal model of Parkinson's disease may be related to a dysregulation of neurotransmitter systems in brain areas related to anxiety. ( Bassani, TB; da Cunha, C; de O Guaita, G; Santiago, RM; Vieira, JCF; Vital, MABF; Zanoveli, JM, 2019) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (10.00) | 18.2507 |
2000's | 3 (10.00) | 29.6817 |
2010's | 17 (56.67) | 24.3611 |
2020's | 7 (23.33) | 2.80 |
Authors | Studies |
---|---|
Zarrindast, MR | 1 |
Fazli-Tabaei, S | 1 |
Khakpai, F | 1 |
Mendes-Pinheiro, B | 1 |
Soares-Cunha, C | 1 |
Marote, A | 1 |
Loureiro-Campos, E | 1 |
Campos, J | 1 |
Barata-Antunes, S | 1 |
Monteiro-Fernandes, D | 1 |
Santos, D | 1 |
Duarte-Silva, S | 1 |
Pinto, L | 1 |
José Salgado, A | 1 |
Abrishamdar, M | 1 |
Farbood, Y | 1 |
Sarkaki, A | 1 |
Rashno, M | 1 |
Badavi, M | 1 |
Li, R | 1 |
Wang, Y | 2 |
Yang, Y | 2 |
Wu, Z | 1 |
Wang, L | 1 |
Tang, G | 1 |
Yang, J | 1 |
Liu, J | 4 |
Cunha, AM | 1 |
Teixeira, FG | 1 |
Guimarães, MR | 1 |
Esteves, M | 1 |
Pereira-Mendes, J | 1 |
Soares, AR | 1 |
Almeida, A | 1 |
Sousa, N | 1 |
Salgado, AJ | 1 |
Leite-Almeida, H | 1 |
G, A | 1 |
O, P | 1 |
E, CM | 1 |
M, GR | 1 |
Antunes, MS | 1 |
Cattelan Souza, L | 1 |
Ladd, FVL | 1 |
Ladd, AABL | 1 |
Moreira, AL | 1 |
Bortolotto, VC | 1 |
Silva, MRP | 1 |
Araújo, SM | 1 |
Prigol, M | 1 |
Nogueira, CW | 1 |
Boeira, SP | 1 |
Slominsky, PA | 1 |
Shadrina, MI | 1 |
Kolomin, TA | 1 |
Stavrovskaya, AV | 1 |
Filatova, EV | 1 |
Andreeva, LA | 1 |
Illarioshkin, SN | 1 |
Myasoedov, NF | 1 |
Sun, YN | 1 |
Yao, L | 1 |
Li, LB | 1 |
Du, CX | 3 |
Guo, Y | 3 |
Zhang, QJ | 1 |
Zhang, J | 2 |
Lv, SX | 2 |
Zhang, YM | 1 |
Loiodice, S | 1 |
Wing Young, H | 1 |
Rion, B | 1 |
Méot, B | 1 |
Montagne, P | 1 |
Denibaud, AS | 1 |
Viel, R | 1 |
Drieu La Rochelle, C | 1 |
Ferrazzo, S | 1 |
Gunduz-Cinar, O | 1 |
Stefanova, N | 1 |
Pollack, GA | 1 |
Holmes, A | 1 |
Schmuckermair, C | 1 |
Ferraguti, F | 1 |
Ogata, M | 1 |
Akita, H | 1 |
Ishibashi, H | 1 |
Vieira, JCF | 1 |
Bassani, TB | 1 |
Santiago, RM | 1 |
de O Guaita, G | 1 |
Zanoveli, JM | 1 |
da Cunha, C | 1 |
Vital, MABF | 1 |
Feng, CW | 1 |
Wen, ZH | 1 |
Huang, SY | 1 |
Hung, HC | 1 |
Chen, CH | 1 |
Yang, SN | 1 |
Chen, NF | 1 |
Wang, HM | 1 |
Hsiao, CD | 1 |
Chen, WF | 1 |
Sullivan, RM | 1 |
Dufresne, MM | 1 |
Siontas, D | 1 |
Chehab, S | 1 |
Townsend, J | 1 |
Laplante, F | 1 |
Chiu, WH | 1 |
Depboylu, C | 1 |
Hermanns, G | 1 |
Maurer, L | 1 |
Windolph, A | 1 |
Oertel, WH | 1 |
Ries, V | 1 |
Höglinger, GU | 1 |
Silva, TP | 1 |
Poli, A | 1 |
Hara, DB | 1 |
Takahashi, RN | 1 |
Dallé, E | 1 |
Daniels, WMU | 1 |
Mabandla, MV | 1 |
Picazo, O | 1 |
Chuc-Meza, E | 1 |
Anaya-Martinez, V | 1 |
Jimenez, I | 1 |
Aceves, J | 1 |
Garcia-Ramirez, M | 1 |
Eskow Jaunarajs, KL | 2 |
Dupre, KB | 1 |
Ostock, CY | 1 |
Button, T | 1 |
Deak, T | 1 |
Bishop, C | 2 |
Yan, J | 1 |
Xu, Y | 1 |
Zhu, C | 1 |
Zhang, L | 1 |
Wu, A | 1 |
Xiong, Z | 1 |
Deng, C | 1 |
Huang, XF | 1 |
Yenari, MA | 1 |
Yang, YG | 1 |
Ying, W | 1 |
Wang, Q | 1 |
Furmaga, H | 1 |
Shah, A | 1 |
Frazer, A | 1 |
George, JA | 1 |
Kuan, WL | 1 |
Zhao, JW | 1 |
Barker, RA | 1 |
Espejo, EF | 2 |
Miñano, J | 1 |
Pappas, BA | 1 |
Murtha, SJ | 1 |
Park, GA | 1 |
Condon, KT | 1 |
Szirtes, RM | 1 |
Laventure, SI | 1 |
Ally, A | 1 |
Steketee, JD | 1 |
Silverman, PB | 1 |
Swann, AC | 1 |
30 other studies available for oxidopamine and Anxiety
Article | Year |
---|---|
Synergistic effect between quinpirole and L-NAME as well as sulpiride and L-arginine on the modulation of anxiety and memory processes in the 6-OHDA mouse model of Parkinson's disease: An isobologram analysis.
Topics: Adrenergic Agents; Animals; Anxiety; Arginine; Disease Models, Animal; Dopamine Agonists; Dopamine A | 2021 |
Unilateral Intrastriatal 6-Hydroxydopamine Lesion in Mice: A Closer Look into Non-Motor Phenotype and Glial Response.
Topics: Animals; Anxiety; Behavior, Animal; Corpus Striatum; Depressive Disorder; Disease Models, Animal; Fe | 2021 |
Evaluation of betulinic acid effects on pain, memory, anxiety, catalepsy, and oxidative stress in animal model of Parkinson's disease.
Topics: Animals; Antioxidants; Anxiety; Betulinic Acid; Brain-Derived Neurotrophic Factor; Catalepsy; Diseas | 2023 |
The α1 and γ2 subunit-containing GABA
Topics: Animals; Anxiety; Dopamine; Dorsal Raphe Nucleus; gamma-Aminobutyric Acid; Oxidopamine; Parkinson Di | 2023 |
Unilateral accumbal dopamine depletion affects decision-making in a side-specific manner.
Topics: Animals; Anxiety; Behavior, Animal; Decision Making; Depression; Dopaminergic Neurons; Impulsive Beh | 2020 |
Reduction of dopaminergic transmission in the globus pallidus increases anxiety-like behavior without altering motor activity.
Topics: Animals; Anxiety; Brain; Depression; Dopamine; Dopamine Agonists; Globus Pallidus; Male; Motor Activ | 2020 |
Hesperidin Ameliorates Anxiety-Depressive-Like Behavior in 6-OHDA Model of Parkinson's Disease by Regulating Striatal Cytokine and Neurotrophic Factors Levels and Dopaminergic Innervation Loss in the Striatum of Mice.
Topics: Animals; Anxiety; Behavior, Animal; Corpus Striatum; Cytokines; Depression; Dopaminergic Neurons; He | 2020 |
Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism.
Topics: Adrenocorticotropic Hormone; Animals; Anxiety; Disease Models, Animal; Dopaminergic Neurons; Male; O | 2017 |
Activation and blockade of basolateral amygdala 5-HT
Topics: Animals; Anti-Anxiety Agents; Anxiety; Basolateral Nuclear Complex; Corpus Striatum; Dopamine; gamma | 2018 |
Involvement of prelimbic 5-HT
Topics: Animals; Anxiety; Apomorphine; Desipramine; Disease Models, Animal; Dopamine Agents; Enzyme Inhibito | 2018 |
Serotonin₆ Receptors in the Prelimbic Cortex are Involved in the Regulation of Anxiety-Like Behaviors in the Rat 6-Hydroxydopamine Parkinson’s Disease Model.
Topics: Animals; Anxiety; Oxidopamine; Parkinson Disease; Rats; Receptors, Serotonin; Serotonin | 2018 |
Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Anxiety; Benserazide; Disease Models, Animal; Dopamine; | 2019 |
Increased anxiety-like behavior following circuit-specific catecholamine denervation in mice.
Topics: Adrenergic Agents; Amygdala; Animals; Anxiety; Catecholamines; Male; Mice; Mice, Inbred C57BL; Oxido | 2019 |
Behavioral responses to anxiogenic tasks in young adult rats with neonatal dopamine depletion.
Topics: Adrenergic Uptake Inhibitors; Animals; Animals, Newborn; Anxiety; Atomoxetine Hydrochloride; Behavio | 2019 |
Anxiety-like behavior induced by 6-OHDA animal model of Parkinson's disease may be related to a dysregulation of neurotransmitter systems in brain areas related to anxiety.
Topics: Adrenergic Agents; Amygdala; Animals; Anxiety; Anxiety Disorders; Behavior, Animal; Brain; Corpus St | 2019 |
Effects of 6-hydroxydopamine exposure on motor activity and biochemical expression in zebrafish (Danio rerio) larvae.
Topics: Animals; Antiparkinson Agents; Anxiety; Biomarkers; Blotting, Western; Carbidopa; Disease Models, An | 2014 |
Mesocortical dopamine depletion and anxiety-related behavior in the rat: sex and hemisphere differences.
Topics: Adrenocorticotropic Hormone; Animals; Anxiety; Dietary Sucrose; Dopamine; Estrous Cycle; Exploratory | 2014 |
Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Anxiety; Benzothiazoles; Depression; Hippocampus; Levodopa; Male; Mic | 2015 |
Time course study of microglial and behavioral alterations induced by 6-hydroxydopamine in rats.
Topics: Acetylglucosaminidase; Animals; Anxiety; Behavior, Animal; Biogenic Monoamines; Corpus Striatum; Dep | 2016 |
Anti-parkinsonian effects of fluvoxamine maleate in maternally separated rats.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Antiparkinson Agents; Anxiety; Disease | 2016 |
6-Hydroxydopamine lesion in thalamic reticular nucleus reduces anxiety behaviour in the rat.
Topics: Analysis of Variance; Animals; Anxiety; Cell Count; Exploratory Behavior; Fear; Immunohistochemistry | 2009 |
Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat.
Topics: Amygdala; Animals; Anxiety; Behavioral Research; Biogenic Monoamines; Chromatography, High Pressure | 2010 |
Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses.
Topics: Animals; Anti-Inflammatory Agents; Anxiety; Apoptosis; Autoradiography; Cell Survival; Disease Model | 2011 |
Serotonergic and noradrenergic pathways are required for the anxiolytic-like and antidepressant-like behavioral effects of repeated vagal nerve stimulation in rats.
Topics: 5,7-Dihydroxytryptamine; Adrenergic Agents; Adrenergic Uptake Inhibitors; Analysis of Variance; Anim | 2011 |
L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Anxiety; Behavior, Animal; Brain; Chromatography, High Pressure Liquid; | 2012 |
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.
Topics: Adrenal Cortex Hormones; Amphetamine; Animals; Anxiety; Blotting, Western; Body Weight; Central Nerv | 2008 |
Selective dopamine depletion within the medial prefrontal cortex induces anxiogenic-like effects in rats placed on the elevated plus maze.
Topics: Animals; Anxiety; Behavior, Animal; Denervation; Dopamine; Male; Maze Learning; Microinjections; Oxi | 1997 |
Adrenergic hyperactivity and metanephrine excess in the nucleus accumbens after prefrontocortical dopamine depletion.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anxiety; Behavior, Animal; Darkness; Dopamine; Epinephrine; | 2001 |
Neonatal brain dopamine depletion and the cortical and behavioral consequences of enriched postweaning environment.
Topics: Animals; Animals, Newborn; Anxiety; Behavior, Animal; Body Weight; Brain Chemistry; Catecholamines; | 1992 |
Noradrenergic receptor mechanisms in neophobia.
Topics: Adenylyl Cyclases; Animals; Anxiety; Behavior, Animal; Clonidine; Colforsin; Dopamine beta-Hydroxyla | 1992 |